Isabelle Mahé: Bleeding Risk Differs Across Solid Tumours in Cancer-Associated Thrombosis
Isabelle Mahé, Head of Internal Medicine at the Louis Mourier Hospital, APHP at Paris Cité University, shared a post on LinkedIn about several recent articles she and her colleagues co-authored, adding:
“Another way to express that bleeding risk varies according to solid cancer site, with a low risk of CRB in breast cancer (6·2%) and a narrow range across other solid tumours (15·4–18·5%) (shown in figure 1 of the original Article recently published in The Lancet Haematology
Please read our reply just published in The Lancet Haematology!
In patients with CAT, reduced-dose apixaban is non inferior to full dose apixaban, and is associated with a significant 25% reduction in the risk of Clinically Relevant Bleeding (published in NEJM Group)”
Title 1: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama, Hélène Helfer, Grigoris Gerotziafas, Silvy Laporte, Eric Vicaut, Patrick Mismetti
Read the Full Article on The Lancet Haematology
Title 2: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE – Authors’ reply
Authors: Isabelle Mahé, Céline Chapelle, Silvy Laporte
Read the Full Article on The Lancet Haematology
Title 3: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez, Claire Grange, Manuel Monreal, Juan J. López-Núñez, Remedios Otero-Candelera, Grégoire Le Gal, Erik Yeo, Marc Righini, Helia Robert-Ebadi, Menno V. Huisman, Frederikus A. Klok, Peter Westerweel, Giancarlo Agnelli, Cecilia Becattini, Aristotelis Bamias, Kostas Syrigos, Sebastian Szmit, Adam Torbicki, Peter Verhamme, Anthony Maraveyas, Alexander T. Cohen, Cihan Ay, Céline Chapelle, Guy Meyer, Francis Couturaud, Patrick Mismetti, Philippe Girard, Laurent Bertoletti, Silvy Laporte
Read the Full Article on The New England Journal of Medicine
Faizan Khan, CIHR Banting Postdoctoral Fellow at University of Calgary, shared on LinkedIn about a recent article he and Nick van Es co-authored, adding:
”In a new publication from my Banting Canada postdoctoral fellowship out today in The Lancet Haematology, Nick van Es and I highlight the importance of considering different cancer sites for bleeding risk stratification in patients with cancer-associated Venous Thromboembolism.”
Title: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE
Authors: Faizan Khan, Nick van Es
Read the Full Article on The Lancet Haematology
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS